<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-section" /><meta name="keywords" content="Fibrinolytic drugs; Enzymes, fibrinolytic; Thrombolytics; Myocardial infarction: management: thrombolytics; Alteplase; rt-PA see Alteplase; TPA see Alteplase; Reteplase; Tenecteplase; Streptokinase; Pulmonary: embolism; Thrombosis: venous; Thromboembolism: pulmonary; Alteplase; Urokinase; Anistreplase" /><meta name="IX" content="Fibrinolytic drugs; Enzymes, fibrinolytic; Thrombolytics; Myocardial infarction: management: thrombolytics; Alteplase; Reteplase; Tenecteplase; Streptokinase; Pulmonary: embolism; Thrombosis: venous; Thromboembolism: pulmonary; Alteplase; Urokinase; Anistreplase" /><meta name="IXN" content="rt-PA see Alteplase; TPA see Alteplase" /><title>2.10.2 Fibrinolytic drugs: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="2813.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="2813.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=2813.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="1002.htm">2 Cardiovascular system</a> &gt; <a href="60549.htm">2.10 Stable angina, acute coronary syndromes, and fibrinolysis</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="204270.htm" title="Previous: Management of ST-segment elevation myocardial infarction (STEMI)">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="2814.htm" title="Next: ALTEPLASE">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_2813">2.10.2 Fibrinolytic drugs</h1><?highlighter on?><div id="pC" class="jN"><div><p>Fibrinolytic drugs act as thrombolytics
by activating plasminogen to form plasmin, which degrades fibrin and
so breaks up thrombi.</p><p>The value of thrombolytic drugs for the treatment of <i>myocardial
infarction</i> has been established (<a title=" Management of myocardial infarction" href="60552.htm#_60552">section 2.10.1</a>). <b>Streptokinase</b> and <b>alteplase</b> have been shown to reduce mortality. <b>Reteplase</b> and <b>tenecteplase</b> are also licensed for acute myocardial
infarction. Thrombolytic drugs are indicated for any patient with
acute myocardial infarction for whom the benefit is likely to outweigh
the risk of treatment. Trials have shown that the benefit is greatest
in those with ECG changes that include ST segment elevation (especially
in those with anterior infarction) and in patients with bundle branch
block. Patients should not be denied thrombolytic treatment on account
of age alone because mortality in the elderly is high and the reduction
in mortality is the same as in younger patients.</p><p><span>Alteplase</span>, <span>reteplase</span> and <span>streptokinase</span> need to be given within 12 hours of symptom
onset, ideally within 1 hour; use after 12 hours requires specialist
advice. Tenecteplase should be given as early as possible and usually
within 6 hours of symptom onset.</p><p>Alteplase, streptokinase, and <b>urokinase</b> can be used for other thromboembolic disorders
such as deep-vein thrombosis and pulmonary embolism. Alteplase is
also used for acute ischaemic stroke (see <a title="BNF:topic: Ischaemic stroke" href="213885.htm#_213885">section 2.9</a>).</p><p>Urokinase is also licensed to restore the patency of occluded
intravenous catheters and cannulas blocked with fibrin clots.</p><div class="cAZ" id="_2813.1"><h2>Cautions</h2> <p class="cAX">Thrombolytic drugs should
be used with caution if there is a risk of bleeding including
that from venepuncture or invasive procedures. They
should also be used with caution in external chest compression, elderly, hypertension, conditions in which thrombolysis might give rise to
embolic complications such as enlarged
left atrium with atrial fibrillation (risk of dissolution of clot
and subsequent embolisation), and recent or concurrent use of drugs that increase the risk of bleeding.</p></div><div class="cAZ" id="_2813.2"><h2>Contra-indications</h2> <p class="cAX">Thrombolytic drugs
are contra-indicated in recent haemorrhage, trauma, or surgery (including dental extraction), coagulation defects, bleeding diatheses, aortic dissection, aneurysm, coma, history of cerebrovascular
disease especially recent events or with any residual disability, recent symptoms of possible peptic ulceration, heavy vaginal bleeding, severe
hypertension, active pulmonary disease with
cavitation, acute pancreatitis, pericarditis, bacterial endocarditis, and oesophageal varices; also in the case
of <span>streptokinase</span>, previous allergic reactions to
either <span>streptokinase</span> or anistreplase (no longer available).</p><div id="_2813.3"> <p class="cAX">Prolonged persistence of antibodies to <span>streptokinase</span> and anistreplase (no longer available) can reduce the effectiveness
of subsequent treatment; therefore, <span>streptokinase</span> should not be
used again beyond 4 days of first administration of either <span>streptokinase</span> or anistreplase.</p></div></div><div id="_203975"><div class="cAZ"><h2>Hepatic impairment</h2> <p class="cAX">Thrombolytic drugs should be
avoided in severe hepatic impairment as there is an increased risk
of bleeding.</p></div></div><div id="_203976"><div class="cAZ"><h2>Pregnancy</h2> <p class="cAX">Thrombolytic drugs can possibly lead
to premature separation of the placenta in the first 18 weeks of pregnancy.
There is also a risk of maternal haemorrhage throughout pregnancy
and post-partum, and also a theoretical risk of fetal haemorrhage
throughout pregnancy.</p></div></div><div id="_2813.4"><div class="cAZ"><h2>Side-effects</h2> <p class="cAX">Side-effects of thrombolytics are
mainly nausea and vomiting and bleeding. When thrombolytics are used
in myocardial infarction, reperfusion arrhythmias and recurrent ischaemia
and angina may occur. Reperfusion may also cause cerebral and pulmonary
oedema. Hypotension can also occur and can usually be controlled by
elevating the patient’s legs, or by reducing the rate of infusion
or stopping it temporarily. Back pain, fever, and convulsions have
been reported. Bleeding is usually limited to the site of injection,
but intracerebral haemorrhage or bleeding from other sites can occur.
Serious bleeding calls for discontinuation of the thrombolytic and
may require administration of coagulation factors and antifibrinolytic
drugs (e.g. <span>tranexamic acid</span>). Rarely further embolism
may occur (either due to clots that break away from the original thrombus
or to cholesterol crystal emboli). Thrombolytics can cause allergic
reactions (including rash, flushing and uveitis) and anaphylaxis has
been reported (for details of management see Allergic Emergencies, <a title=" Allergic emergencies" href="3121.htm#_3121">section 3.4.3</a>). Guillain-Barré syndrome has been reported
rarely after <span>streptokinase</span> treatment.</p></div></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_2814"><a href="2814.htm" title="ALTEPLASE">ALTEPLASE</a></li><li id="_60577"><a href="60577.htm" title="RETEPLASE">RETEPLASE</a></li><li id="_2818"><a href="2818.htm" title="STREPTOKINASE">STREPTOKINASE</a></li><li id="_106045"><a href="106045.htm" title="TENECTEPLASE">TENECTEPLASE</a></li><li id="_130134"><a href="130134.htm" title="UROKINASE">UROKINASE</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="204270.htm">Previous: Management of ST-segment elevation myocardial infarction (STEMI)</a> | <a class="top" href="2813.htm#">Top</a> | <a accesskey="]" href="2814.htm">Next: ALTEPLASE</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>